Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2003 2
2006 2
2007 9
2008 9
2009 6
2010 4
2011 13
2012 22
2013 10
2014 12
2015 12
2016 10
2017 12
2018 8
2019 13
2020 12
2021 21
2022 17
Text availability
Article attribute
Article type
Publication date

Search Results

178 results
Results by year
Filters applied: . Clear all
Page 1
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.
Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH. Fuchs CS, et al. Among authors: yoon hh. JAMA Oncol. 2018 May 10;4(5):e180013. doi: 10.1001/jamaoncol.2018.0013. Epub 2018 May 10. JAMA Oncol. 2018. PMID: 29543932 Free PMC article. Clinical Trial.
Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials.
Chao J, Fuchs CS, Shitara K, Tabernero J, Muro K, Van Cutsem E, Bang YJ, De Vita F, Landers G, Yen CJ, Chau I, Elme A, Lee J, Özgüroglu M, Catenacci D, Yoon HH, Chen E, Adelberg D, Shih CS, Shah S, Bhagia P, Wainberg ZA. Chao J, et al. Among authors: yoon hh. JAMA Oncol. 2021 Jun 1;7(6):895-902. doi: 10.1001/jamaoncol.2021.0275. JAMA Oncol. 2021. PMID: 33792646 Free PMC article.
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.
Bang YJ, Kang YK, Catenacci DV, Muro K, Fuchs CS, Geva R, Hara H, Golan T, Garrido M, Jalal SI, Borg C, Doi T, Yoon HH, Savage MJ, Wang J, Dalal RP, Shah S, Wainberg ZA, Chung HC. Bang YJ, et al. Among authors: yoon hh. Gastric Cancer. 2019 Jul;22(4):828-837. doi: 10.1007/s10120-018-00909-5. Epub 2019 Mar 25. Gastric Cancer. 2019. PMID: 30911859 Free PMC article. Clinical Trial.
Trifluridine/tipiracil plus ramucirumab in gastric cancer.
Zhu M, Sonbol MB, Yoon HH. Zhu M, et al. Among authors: yoon hh. Lancet Gastroenterol Hepatol. 2021 Mar;6(3):154-155. doi: 10.1016/S2468-1253(21)00013-3. Epub 2021 Jan 26. Lancet Gastroenterol Hepatol. 2021. PMID: 33508243 Free PMC article. No abstract available.
Antiangiogenic Therapy in Gastroesophageal Cancer.
Jin Z, Yoon HH. Jin Z, et al. Among authors: yoon hh. Hematol Oncol Clin North Am. 2017 Jun;31(3):499-510. doi: 10.1016/j.hoc.2017.01.008. Epub 2017 Mar 22. Hematol Oncol Clin North Am. 2017. PMID: 28501090 Review.
Ramucirumab plus paclitaxel for gastric cancer in China.
Yoon HH. Yoon HH. Lancet Gastroenterol Hepatol. 2021 Dec;6(12):975-976. doi: 10.1016/S2468-1253(21)00342-3. Epub 2021 Oct 7. Lancet Gastroenterol Hepatol. 2021. PMID: 34626551 No abstract available.
Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction.
Zhu M, Chen C, Foster NR, Hartley C, Mounajjed T, Salomao MA, Fruth BF, Beamer SE, Kim Y, Harrington SM, Pitot HC, Sanhueza CT, Feng Y, Herrmann J, McWilliams RR, Lucien F, Huang BQ, Ma WW, Bekaii-Saab TS, Dong H, Wigle D, Ahn DH, Hallemeier CL, Blackmon S, Yoon HH. Zhu M, et al. Among authors: yoon hh. Clin Cancer Res. 2022 Jul 15;28(14):3021-3031. doi: 10.1158/1078-0432.CCR-22-0413. Clin Cancer Res. 2022. PMID: 35552651 Clinical Trial.
178 results